Get the Stockscreener App
21.62
1.03%
0.22
After Hours:
21.62
Syndax Pharmaceuticals Inc stock is traded at $21.62, with a volume of 1.03M.
It is up +1.03% in the last 24 hours and up +5.82% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$21.40
Open:
$21.39
24h Volume:
1.03M
Relative Volume:
0.76
Market Cap:
$1.88B
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-7.3041
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
+4.19%
1M Performance:
+5.82%
6M Performance:
+33.54%
1Y Performance:
+50.35%
1-Day Range:
$21.00
$21.91
1-Week Range:
$19.21
$22.68
52-Week Range:
$8.58
$22.73
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
21.62 | 1.86B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | H.C. Wainwright | Buy |
| Sep-10-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Syndax Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-03-03 - Seeking Alpha
Is Syndax Pharmaceuticals (SNDX) Pricing Reflect Pipeline Progress Or Stretching Recent Share Gains - simplywall.st
SNDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SNDX Receives Buy Rating as Citigroup Raises Price Target to $57 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $57.00 Price Target at Citigroup - MarketBeat
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs - Bitget
Syndax’s Third FDA Win Accelerates Shift To Multi Product Revenues - Sahm
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2025 Earnings Call Transcript - Insider Monkey
Barclays Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX) - The Globe and Mail
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Syndax Pharmaceuticals (NASDAQ:SNDX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? - Yahoo Finance
Syndax (SNDX) Q4 2025 Earnings Call Transcript - Intellectia AI
Syndax Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Syndax Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Discipline and Rules-Based Execution in SNDX Response - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Syndax Pharmaceuticals (SNDX) Reports Strong 2025 Earnings and Growth Prospects - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Results - MarketBeat
Syndax Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Syndax (SNDX) Projects Stable Operating Expenses and Path to Pro - GuruFocus
Syndax (SNDX) Exceeds Revenue Expectations, Anticipates Continued Growth - GuruFocus
Syndax Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q4 2025 Syndax Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings Flash (SNDX) Syndax Pharmaceuticals, Inc. Reports Q4 Revenue $68.7M, vs. FactSet Est of $64.3M - marketscreener.com
BRIEF-Syndax Pharmaceuticals Q4 Operating Expenses USD 131.276 Million - TradingView
Cancer drug maker Syndax posts $172M sales, eyes profitability - Stock Titan
Syndax faces earnings test as cancer drug launches accelerate By Investing.com - Investing.com UK
Syndax faces earnings test as cancer drug launches accelerate - Investing.com India
Syndax: Overview of Fourth Quarter Financial Results - Bitget
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Syndax Pharmaceuticals, Inc. announces that patient enrollment has been completed for its Phase II clinical trial of Axatilimab for idiopathic pulmonary fibrosis (IPF). - Bitget
VIX Spike: Is Syndax Pharmaceuticals Inc stock showing strong momentumBull Run & High Yield Equity Trading Tips - baoquankhu1.vn
Biotech CEO plans three March investor Q&As in Boston and Miami - Stock Titan
Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Monday - Defense World
Aberdeen Group plc Grows Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Is Syndax Pharmaceuticals Inc. a speculative investment2025 Price Momentum & Accurate Trade Setup Notifications - mfd.ru
Earnings Miss: Does Syndax Pharmaceuticals Inc. have strong fundamentalsQuarterly Investment Review & Safe Capital Investment Plans - mfd.ru
Can Syndax Pharmaceuticals Inc. stock double in the next yearInsider Selling & Precise Trade Entry Recommendations - mfd.ru
Syndax Pharmaceuticals (SNDX) Stock Analysis: An 88% Potential Upside Ignites Investor Interest - DirectorsTalk Interviews
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call ... - Bluefield Daily Telegraph
Syndax to Announce Fourth Quarter and Full Year 2025 - GlobeNewswire
Cancer drug maker Syndax to review 2025 results in Feb. 26 earnings call - Stock Titan
Syndax Pharmaceuticals Highlights Revuforj, Niktimvo Sales Surge and 2026 Milestones at Guggenheim Conf - Defense World
Why Analysts See Syndax Pharmaceuticals (SNDX) Story Evolving With New Deals And Refined Valuation - Yahoo Finance
Behavioral Patterns of SNDX and Institutional Flows - Stock Traders Daily
How Revuforj’s Global Access Push At Syndax Pharmaceuticals (SNDX) Has Changed Its Investment Story - Sahm
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):